

LETTER TO THE EDITOR

Organ transplantation from deceased donors with vaccine-induced thrombosis and thrombocytopenia

To the Editor:

Vaccine-induced thrombosis and thrombocytopenia (VITT) may follow immunization with the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2.^{1,2} Autoantibodies to platelet factor 4 (PF4) may mediate VITT through antibody-dependent platelet activation, though the underlying etiology is uncertain.³ Anti-PF4 antibodies are also seen in heparin-induced thrombocytopenia, though most cases of VITT do not have prior heparin exposure. More than 20 million people in the United Kingdom (UK) have received the ChAdOx1 nCoV-19 vaccine. We carried out an early analysis of organ donation and transplantation from UK donors with VITT, to understand the implications of this emerging syndrome. Articles 6(1)(e) and 9(2)(h) and (i) of the General Data Protection Regulations provide the basis for NHSBT to use patient identifiable data without prior consent, for the purposes of monitoring the safety of the national transplant program.

We identified 13 consented deceased organ donors, who presented with thrombosis and/or hemorrhage and laboratory features consistent with VITT,⁴ between 28 January and 9 April 2021. All had received their first dose of ChAdOx1 nCoV-19 vaccine before admission (see Table 1). Ten donors proceeded to donate 27 allografts to 26 recipients. After a median follow-up of 19 days, 21 of 27 (78%) allografts have satisfactory function. Three recipients developed early allograft failure requiring explantation (two livers and one kidney); two transplanted kidneys have impaired allograft function, currently requiring hemodialysis; and one recipient died within a day of transplantation from a presumed cardiac event. There were seven major thrombotic or hemorrhagic postoperative complications (three bleeds and four venous or arterial allograft thromboses) in six recipients, resulting in the loss of three transplants as described above; these events occurred within 9 days of transplantation. Of the six recipients with bleeding or thrombotic events, two had received their second dose of ChAdOx1 nCoV-19 vaccine within 30 days before transplantation; neither patient had features suggestive of VITT at the time of transplantation. Two of the three patients with bleeding had preexisting risk factors for hemorrhage (dual antiplatelet agent therapy, anticoagulation for metallic cardiac valve); none of the

patients with thromboses had significant preexisting procoagulant tendencies.

So far, three liver recipients had detectable anti-PF4 antibodies between 3 and 22 days posttransplant; one of these recipients experienced a thrombotic complication without allograft loss and the other two had uncomplicated postoperative courses. Ten recipients (six kidneys and four livers) tested negative for anti-PF4 antibodies.

The UK experience to date suggests that the potential risks of transplanting organs from donors with VITT are twofold. First, early major thrombosis or clinically significant bleeding, which may result from preexisting hemostatic and endothelial dysfunction in the allograft. Second, possible transmission of pathogenic lymphocytes producing anti-PF4. The clinical significance of this is unclear; further follow-up will determine whether this portends development of VITT in the recipient.

UK guidance has been drawn up for the selection, recovery, and transplantation of organs from donors with VITT, as well as recipient monitoring.⁵ We suggest that liver, lung, pancreas, and small bowel transplants from donors with VITT should only proceed in urgent situations, as these organs contain high numbers of "passenger" donor lymphocytes. Since anti-PF4 antibodies can provoke platelet activation and thromboses, platelet transfusion should be avoided during organ recovery and transplantation processes where possible. The contribution of systemic heparinization during organ recovery to thrombosis within the allograft is uncertain, and argatroban is an alternative anticoagulant.⁵ Current UK guidance recommends that heparin can be used as per standard practice in the recipient unless features of VITT develop.⁵ For recipients of organs from VITT donors, monitoring of the platelet count, fibrinogen, D-dimers, and anti-PF4 antibodies is essential.⁵

Further experience of organ transplantation from donors with VITT and longer term recipient follow-up will help guide clinical decision-making. In the meantime, transplantation of organs from these donors should only proceed after careful consideration of the methods for organ recovery and of the risks and benefits for a potential recipient, and an appropriate consent discussion.

*Joint first author.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. *American Journal of Transplantation* published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons

TABLE 1 Deceased donors with VITT and the recipients of their organs

Characteristic	Value
Consented deceased donors ^a	13 ^b
Age (years)	34 (21 to 63)
Female	11 (85%)
Donation after brain death	13 (100%)
Time from vaccine administration to hospital admission (days)	10 (7 to 18)
Clinical features ^c	
Intracranial hemorrhage	12 (92%)
Cerebral venous sinus thrombosis	7 (54%)
Extra-cranial thrombosis ^d	6 (46%)
Platelet count ($\times 10^9/L$)	
On admission to hospital	26 (3 to 61)
Lowest value prior to donation	7 (2 to 50)
Fibrinogen (g/L, NR 2 to 4) ^e	1.0 (<0.3 to 4.5)
D-dimer (ng/ml, NR < 500) ^f	41 000 (6500 to >80 000)
Anti-PF4 antibodies (OD, assay cut-off 0.4) ^g	2.7 (1.4 to 3.2)
Transplant recipients	26
Age (years)	40 (2 to 63)
Female	12 (46%)
Transplant type	
Kidney-only	15
Liver ^h	7
Heart	1
Bilateral lung	1
Simultaneous pancreas and kidney (SPK)	1
Pancreatic islet	1
Major postoperative complications ⁱ	7
Liver recipients	
Major hemorrhage	0
Thrombosis/thromboembolism	3
Kidney/SPK/islet recipients	
Major hemorrhage	3
Thrombosis/thromboembolism	1
Heart/lung recipients	
Major hemorrhage	0
Thrombosis/thromboembolism	0
Patient and allograft outcomes	
Delayed graft function/early graft dysfunction ^j	4
Graft explant	3
Death	1
Lowest postoperative platelet count ($\times 10^9/L$) ^k	124 (32 to 267)
Anti-PF4 antibodies ^g	
Positive	3
Negative	10

Characteristic	Value
Result pending	2
Not tested	11

Note: Numbers are *n* (%) or median (range).

Abbreviations: VITT, vaccine-induced thrombosis and thrombocytopenia; NR, normal range; PF4, platelet factor 4; OD, optical density units.

^aIndividuals in whom consent for organ donation has been granted.

^bAll organ offers from one donor were declined, so no organs were retrieved. Two donors had organs retrieved that were not eventually transplanted. Ten donors donated at least one organ that was transplanted.

^cClinical features are not exclusive; six donors presented with intracranial hemorrhage only.

^dPortal vein (2), pulmonary embolus (1), splenic vein (1), mesenteric vein (1), aorta (1).

^eLowest result reported by donor center.

^fHighest result reported by donor center.

^gDonor serum samples from all probable cases were centrally tested by NHSBT for anti-PF4 antibodies, using the Lifecodes PF4 IgG enzyme-linked immunosorbent assay (ELISA, Immucor).

^hIncludes two split liver transplants from one donor.

ⁱNumbers represent events; some recipients experienced more than one complication. Excludes death.

^jDefined as at least one session of hemodialysis/hemofiltration in the first 7 postoperative days in kidney recipients, any need for ongoing extracorporeal membrane oxygenation in heart/lung recipients, or super-urgent listing for re-do transplantation in liver recipients. Excludes graft failure/explant.

^kIn the first 2 weeks after transplantation.

KEYWORDS

autoantibody, clinical research/practice, coagulation and hemostasis, donors and donation: donor follow-up, infection and infectious agents – viral: influenza, kidney transplantation/nephrology, liver transplantation/hepatology

ACKNOWLEDGMENTS

The authors are grateful to the organ donation teams, specialist nurses in organ donation, National Organ Retrieval Service teams, and the staff of the platelet immunology laboratory at NHSBT Filton who assisted with aspects of donor characterization. They also thank the recipient transplant coordinators, and other members of the transplant teams caring for the transplant recipients, who supplied follow-up information required for this study. Lastly, and most of all, they thank all deceased donors and their families.

DISCLOSURE






The authors of this manuscript have no conflicts of interest to disclose as described by the *American Journal of Transplantation*.

UK Donor VITT Transplant Study Group

George H. B. Greenhall^{1*} 

Ines Ushiro-Lumb^{2*} 

Sue Pavord³

Ian Currie¹ 
 M. Thamara P. R. Perera⁴
 Hermien Hartog⁴
 Quentin A. Hill⁵
 Ismail Mohamed⁶
 Muhammad A. Khurram⁶ 
 Reza Motalebzadeh⁷
 Gareth Jones⁷
 Aileen Marshall⁷
 Joerg-Matthias Pollok⁷
 Nicholas Torpey⁸
 Gavin J. Pettigrew⁸
 Sanjay Mehra⁹
 Hemant Sharma⁹
 Francis Calder¹⁰
 Nicos Kessar¹⁰ 
 Jay Nath¹¹
 Debabrata Roy¹²
 Gabriel C. Oniscu¹³ 
 Marc Clancy¹⁴
 Karthik Santhanakrishnan¹⁵
 Jorge Mascaro⁴
 Sern Lim⁴
 Marius Berman¹⁶
 Sue Madden¹
 Lisa Mumford¹
 Darius Mirza⁴
 Chris Watson⁸ 
 Olive McGowan¹
 Douglas Thorburn⁷
 Rommel Ravanan¹ 
 Beverley J. Hunt¹⁰
 Chris J. Callaghan¹ 
 David J. Roberts¹⁷
 John Forsythe¹

¹NHS Blood and Transplant, Bristol, UK

Email: george.greenhall@nhsbt.nhs.uk

²NHS Blood and Transplant, London, UK

³Oxford University Hospitals, Oxford, UK

⁴Queen Elizabeth Hospital, Birmingham, UK

⁵St James's University Hospital, Leeds, UK

⁶Royal London Hospital, London, UK

⁷Royal Free Hospital, London, UK

⁸Addenbrooke's Hospital, Cambridge, UK

⁹Royal Liverpool University Hospital, Liverpool, UK

¹⁰Guy's Hospital, London, UK

¹¹Southmead Hospital, Bristol, UK

¹²University Hospital, Coventry, UK

¹³Royal Infirmary of Edinburgh, Edinburgh, UK

¹⁴Queen Elizabeth University Hospital, Glasgow, UK

¹⁵Wythenshawe Hospital, Manchester, UK

¹⁶Royal Papworth Hospital, Cambridge, UK

¹⁷NHS Blood and Transplant, Oxford, UK

ORCID

George H. B. Greenhall  <https://orcid.org/0000-0002-4816-1474>

Ines Ushiro-Lumb  <https://orcid.org/0000-0003-0989-8091>

Ian Currie  <https://orcid.org/0000-0003-1636-6130>

Muhammad A. Khurram  <https://orcid.org/0000-0002-3555-0374>

Nicos Kessar  <https://orcid.org/0000-0002-4067-7003>

Gabriel C. Oniscu  <https://orcid.org/0000-0003-1714-920X>

Chris Watson  <https://orcid.org/0000-0002-0590-4901>

Rommel Ravanan  <https://orcid.org/0000-0003-3324-9024>

Chris J. Callaghan  <https://orcid.org/0000-0003-3334-4152>

REFERENCES

- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;384(22):2092-2101.
- Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;384(22):2124-2130.
- Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;384(23):2202-2211.
- British Society for Haematology. Guidance produced from the Expert Haematology Panel (EHP) focussed on Covid-19 Vaccine induced Thrombosis and Thrombocytopenia (VITT). 2021(v1.3). <https://b-s-h.org.uk/about-us/news/guidance-produced-by-the-expert-haematology-panel-ehp-focussed-on-vaccine-induced-thrombosis-and-thrombocytopenia-vitt/>. Accessed May 14, 2021.
- NHS Blood and Transplant. Organ Donation and Transplantation from Patients with Vaccine Induced Thrombosis and Thrombocytopenia (VITT) (INF1569/2). <https://www.odt.nhs.uk/covid-19-advice-for-clinicians/>. Accessed May 16, 2021.